neotiv

About neotiv

neotiv GmbH, a digital health company established in 2017, is focused on the early detection of neurodegenerative conditions like Alzheimer's disease. The company originated as a spin-off from the Otto von Guericke University in Magdeburg, Germany, in close collaboration with the German Center for Neurodegenerative Diseases (DZNE). The founding team consists of Dr. Chris Rehse, Prof. Dr. med. Emrah Düzel, and Dr. David Berron, who combined their expertise in science, medicine, and entrepreneurship. Rehse, the CEO, has a background in business and biomedical engineering, with postdoctoral experience at Stanford University and a history of co-founding other ventures. Düzel, a neurologist and prominent dementia researcher, and Berron, a cognitive neuroscientist, contribute deep scientific and clinical knowledge from their work at the DZNE and various universities.

neotiv's core offering is a digital platform featuring scientifically validated cognitive tests delivered via a mobile application, neotivCare. This CE-marked medical device is designed for individuals experiencing subjective cognitive decline, allowing them to perform sensitive memory tests from home. The tests, which involve tasks like memorizing visual information, are performed weekly over a twelve-week period to track memory performance longitudinally. This method aims to distinguish between normal age-related memory changes and the early signs of dementia, providing valuable data for patients and their physicians. Unlike traditional paper-and-pencil tests, neotiv's application targets specific brain regions affected in the early stages of Alzheimer's, offering a more precise assessment.

The company operates in the digital health and e-health market, serving multiple client types. For individuals and physicians, neotivCare provides a tool for early diagnosis and monitoring. In Germany, the app can be prescribed by doctors and is covered under certain health insurance contracts. For pharmaceutical companies and clinical researchers, the platform offers a way to screen trial participants more efficiently and monitor treatment effects with high frequency. The business has secured $10 million in funding across two seed rounds, with notable investors including High-Tech Gründerfonds (HTGF), Capricorn Partners, and bmp Ventures. This capital is being used to expand the availability of neotivCare, pursue international growth, and further develop its platform solutions.